Nothing Special   »   [go: up one dir, main page]

WO1991009872A3 - Polypeptides selectivement reactifs avec des anticorps contre le virus d'immunodeficience humaine et vaccins comprenant les polypeptides - Google Patents

Polypeptides selectivement reactifs avec des anticorps contre le virus d'immunodeficience humaine et vaccins comprenant les polypeptides

Info

Publication number
WO1991009872A3
WO1991009872A3 PCT/US1990/007210 US9007210W WO9109872A3 WO 1991009872 A3 WO1991009872 A3 WO 1991009872A3 US 9007210 W US9007210 W US 9007210W WO 9109872 A3 WO9109872 A3 WO 9109872A3
Authority
WO
WIPO (PCT)
Prior art keywords
hiv
fusion protein
fragment fusion
env fragment
protein
Prior art date
Application number
PCT/US1990/007210
Other languages
English (en)
Other versions
WO1991009872A2 (fr
WO1991009872A1 (fr
Inventor
Avigdor Shafferman
Original Assignee
Univax Biolog Inc
Avigdor Shafferman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23786972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1991009872(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univax Biolog Inc, Avigdor Shafferman filed Critical Univax Biolog Inc
Priority to KR1019920701393A priority Critical patent/KR920703102A/ko
Priority to AU70333/91A priority patent/AU653926B2/en
Publication of WO1991009872A2 publication Critical patent/WO1991009872A2/fr
Publication of WO1991009872A1 publication Critical patent/WO1991009872A1/fr
Publication of WO1991009872A3 publication Critical patent/WO1991009872A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/974—Aids related test
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/22—Viral peptide or viral protein
    • Y10S930/221—Retrovirus related, or human immunodeficiency virus related, or simian immunodeficiency virus related

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Laminated Bodies (AREA)
  • Adhesives Or Adhesive Processes (AREA)

Abstract

On joint (par exemple, par génie génétique) des séquences de polypeptides bien conservées, dérivées de la gp41 et de la gp120, d'une longueur comprise de préférence entre 11 et 21 acides aminés, à une séquence de protéines ou de polypeptides de non-VIH, comprenant une séquence d'acide aminé non codée naturellement par le génome du VIH, formant ainsi une protéine de fusion. Ladite protéine de fusion possède des attributs les rendant adaptés à un emploi dans le diagnostic, le traitement et la prévention d'infections dues au VIH.
PCT/US1990/007210 1989-12-13 1990-12-13 Polypeptides selectivement reactifs avec des anticorps contre le virus d'immunodeficience humaine et vaccins comprenant les polypeptides WO1991009872A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1019920701393A KR920703102A (ko) 1989-12-13 1990-12-13 인간 면역결핍 바이러스(human immunodeficiency virus)에 대한 항체와 선택적으로 반응하는 폴리펩타이드 및 그를 함유하는 백신(vaccines)
AU70333/91A AU653926B2 (en) 1989-12-13 1990-12-13 HIV-1 ENV fragment fusion protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/450,150 US6248574B1 (en) 1989-12-13 1989-12-13 Polypeptides selectively reactive with antibodies against human immunodeficiency virus and vaccines comprising the polypeptides
US450,150 1989-12-13

Publications (3)

Publication Number Publication Date
WO1991009872A2 WO1991009872A2 (fr) 1991-07-11
WO1991009872A1 WO1991009872A1 (fr) 1991-07-11
WO1991009872A3 true WO1991009872A3 (fr) 1992-04-02

Family

ID=

Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US874913A (en) * 1907-03-04 1907-12-24 John H Dale Starter for explosion-motors.
WO1986002383A1 (fr) * 1984-10-18 1986-04-24 Institut Pasteur Antigenes d'enveloppe du virus des lymphadenopathies et leurs applications
WO1986006414A1 (fr) * 1985-04-29 1986-11-06 Genetic Systems Corporation Antigenes synthetiques permettant la detection d'une infection apparentee au sida
EP0214709A2 (fr) * 1985-09-11 1987-03-18 United Biomedical Inc. Peptide synthétique et procédé pour son utilisation dans la détection d'anticorps de HTLV-III, le diagnostic de SIDA et pré-SIDA et comme vaccin
WO1987002775A1 (fr) * 1985-10-24 1987-05-07 Southwest Foundation For Biomedical Research Peptides synthetiques et leur utilisation pour le diagnostic et la vaccination contre le sida et son complexe associe
EP0227169A2 (fr) * 1985-12-17 1987-07-01 Akzo N.V. Réactif immunochimique
EP0231914A2 (fr) * 1986-02-03 1987-08-12 F. Hoffmann-La Roche Ag Peptides d'enveloppe de HTLV-III
WO1987006005A1 (fr) * 1986-03-24 1987-10-08 Ortho Pharmaceutical Corporation Peptides synthetiques utiles pour combattre l'htlv-iii, compositions et utilisations desdits peptides
EP0251612A2 (fr) * 1986-06-23 1988-01-07 Bristol-Myers Squibb Company Anticorps monoclonal humain contre le virus associé à la lymphadénopathie
WO1988000471A1 (fr) * 1986-07-21 1988-01-28 Southwest Foundation For Biomedical Research Composition et procede d'immunisation contre des agents pathogenes viraux du sida et de l'arc
WO1988008005A1 (fr) * 1987-04-16 1988-10-20 Johnson & Johnson Polypeptides se rapportant au stlv-iii, systemes de diagnostic et methodes d'analyse
EP0305777A2 (fr) * 1987-08-14 1989-03-08 BEHRINGWERKE Aktiengesellschaft Synthèse d'antigènes du virus d'immunodéficience humaine du type 1 ainsi que leur utilisation comme agent de diagnostic et thérapeutique
WO1989002277A2 (fr) * 1987-08-28 1989-03-23 Board Of Regents, The University Of Texas System Prophylaxie et therapie du syndrome immunodeficitaire acquis
WO1989003844A1 (fr) * 1987-10-28 1989-05-05 Ferring Ab Peptide de vih, antigenes artificiels de vih et kits d'immunodosage
EP0330359A2 (fr) * 1988-02-25 1989-08-30 Bio-Rad Laboratories, Inc. Composition utile pour le diagnostic et le traitement de l'infection par le HIV-I
EP0335134A2 (fr) * 1988-03-30 1989-10-04 Abbott Laboratories Anticorps monoclonal de souris contre la protéine gp41 du virus d'immunodéficience humaine
WO1989009393A1 (fr) * 1988-03-24 1989-10-05 Igen, Inc. Proteines chimeriques luminescentes
EP0345792A2 (fr) * 1988-06-10 1989-12-13 F. Hoffmann-La Roche Ag Protéines fusionnées HTLV-I/HIV-I
EP0362909A2 (fr) * 1988-08-26 1990-04-11 Akzo N.V. Polypeptides synthétiques immuno-actifs avec des anticorps VIH

Patent Citations (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US874913A (en) * 1907-03-04 1907-12-24 John H Dale Starter for explosion-motors.
WO1986002383A1 (fr) * 1984-10-18 1986-04-24 Institut Pasteur Antigenes d'enveloppe du virus des lymphadenopathies et leurs applications
WO1986006414A1 (fr) * 1985-04-29 1986-11-06 Genetic Systems Corporation Antigenes synthetiques permettant la detection d'une infection apparentee au sida
EP0214709A2 (fr) * 1985-09-11 1987-03-18 United Biomedical Inc. Peptide synthétique et procédé pour son utilisation dans la détection d'anticorps de HTLV-III, le diagnostic de SIDA et pré-SIDA et comme vaccin
WO1987002775A1 (fr) * 1985-10-24 1987-05-07 Southwest Foundation For Biomedical Research Peptides synthetiques et leur utilisation pour le diagnostic et la vaccination contre le sida et son complexe associe
EP0227169A2 (fr) * 1985-12-17 1987-07-01 Akzo N.V. Réactif immunochimique
EP0231914A2 (fr) * 1986-02-03 1987-08-12 F. Hoffmann-La Roche Ag Peptides d'enveloppe de HTLV-III
WO1987006005A1 (fr) * 1986-03-24 1987-10-08 Ortho Pharmaceutical Corporation Peptides synthetiques utiles pour combattre l'htlv-iii, compositions et utilisations desdits peptides
EP0251612A2 (fr) * 1986-06-23 1988-01-07 Bristol-Myers Squibb Company Anticorps monoclonal humain contre le virus associé à la lymphadénopathie
WO1988000471A1 (fr) * 1986-07-21 1988-01-28 Southwest Foundation For Biomedical Research Composition et procede d'immunisation contre des agents pathogenes viraux du sida et de l'arc
WO1988008005A1 (fr) * 1987-04-16 1988-10-20 Johnson & Johnson Polypeptides se rapportant au stlv-iii, systemes de diagnostic et methodes d'analyse
EP0305777A2 (fr) * 1987-08-14 1989-03-08 BEHRINGWERKE Aktiengesellschaft Synthèse d'antigènes du virus d'immunodéficience humaine du type 1 ainsi que leur utilisation comme agent de diagnostic et thérapeutique
WO1989002277A2 (fr) * 1987-08-28 1989-03-23 Board Of Regents, The University Of Texas System Prophylaxie et therapie du syndrome immunodeficitaire acquis
WO1989003844A1 (fr) * 1987-10-28 1989-05-05 Ferring Ab Peptide de vih, antigenes artificiels de vih et kits d'immunodosage
EP0330359A2 (fr) * 1988-02-25 1989-08-30 Bio-Rad Laboratories, Inc. Composition utile pour le diagnostic et le traitement de l'infection par le HIV-I
WO1989009393A1 (fr) * 1988-03-24 1989-10-05 Igen, Inc. Proteines chimeriques luminescentes
EP0335134A2 (fr) * 1988-03-30 1989-10-04 Abbott Laboratories Anticorps monoclonal de souris contre la protéine gp41 du virus d'immunodéficience humaine
EP0345792A2 (fr) * 1988-06-10 1989-12-13 F. Hoffmann-La Roche Ag Protéines fusionnées HTLV-I/HIV-I
EP0362909A2 (fr) * 1988-08-26 1990-04-11 Akzo N.V. Polypeptides synthétiques immuno-actifs avec des anticorps VIH

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
AIDS, Vol. 3, 1989, Dani P. Bolognesi: "HIV antibodies and vaccine design ", pages 111-118. *
Chemical Abstracts, volume 105, no. 21, 24 November 1986, (Columbus, Ohio, US), Wang, james J. G. et al. : "Detection of antibodies to human T-lymphotropic virus type III by using a synthetic peptide of 21 amino acid residues corresponding to a highly antigenic segment of gp41 envelope protein ", see page 543, abstract 188911m, & Proc. Natl. Acad. Sci. 1986, 83(16). *
Chemical Abstracts, volume 107, no. 25, 21 December 1987, (Columbus, Ohio, US), Gnann, John W., Jr. et al. : "Diagnosis of AIDS by using a 12-amino acid peptiderepresenting an immunodominant epitope of the human immunodeficiency virus ", see page 590, abstract 234358c, & J. Infect. Dis. 1987, 156( 2), 261-267 *
Chemical Abstracts, volume 107, no. 55, 3 August 1987, (Columbus, Ohio, US), Palker, Thomas J. et al. : "A conserved region at the carboxy terminus of human immunodeficiency virus gp 120 envelope protein contains an immunodominant epitope ", see page 514, abstract 37664y, & Proc. Natl. Acid. Sci. 1987, 84(8), 2479-2483 *
Chemical Abstracts, volume 109, no. 17, 24 October 1988, (Columbus, Ohio, US), Klasse, Per Johan et al. : "Presence of antibodies to a putatively immunosuppressive part of human immunodeficiency virus (HIV) envelope glycoprotein gp41 is strongly associated with health among HIV-positive subjects ", see page 560, abstract 147593y, & Proc. Natl. Acad. Sci. 1988, 85(14). *
Chemical Abstracts, volume 110, no. 19, 8 May 1989, (Columbus, Ohio, US), see page 639, abstract 171673r, & US, A, 874913 (Synthetic peptides and antibodies for diagnosis ofAIDS and for vaccines) 15 April 1988 *
Chemical Abstracts, volume 111, no. 15, 9 October 1989, (Columbus, Ohio, US), Ruegg, Curtis L et al. : "Inhibition of lymphoproliferation by a synthetic peptide with sequence identity to gp41 of human immunodeficiency virus type 1 ", see page 602, abstract 132340f, & Virol. 1989, 63( 8), 3257-3260 *
Chemical Abstracts, volume 111, no. 9, 28 August 1989, (Columbus, Ohio, US), Shafferman, Avigdor et al. : "Patterns of antibody recognition of selected conserved amino acid sequences from the HIV envelope in sera from different stagesof HIV infection ", see page 576, abstract 76027v, & AIDS Res. Hum. Retroviruses 1989, 5( 1), 33- 3 *
Chemical Abstracts, volume 112, no. 11, 12 March 1990, (Columbus, Ohio, US), Norrby, Erling et al. : "The chemistry of site-directed serology for HIV infections ", see page 591, abstract 96724u, & AIDS Res. Hum. Retroviruses 1989, 5( 5), 487-493. *
Chemical Abstracts, volume 113, no. 21, 19 November 1990, (Columbus, Ohio, US), Hunt, J. C. et al. : "Mouse monoclonal antibody 5-21-3 recognizes a contiguous, conformation-dependent epitope and maps to a hydrophilic region in HIV-1 gp41 ", see page 529, abstract 189272f, & AIDS Res. Hum. Retroviruses 1990, 62(5), 587-598 *
Dialog Informational Service, File 157: AIDSLINE, accession no. 06475126, Lenz, A et al: "Serologic AIDS diagnosis with polypeptides obtained by genetictechnics of the human immunodeficiency virus (HIV-1)A", & Klin Wochensohr Nov 2 1987, 68 (21) p1042-7. *
Nature, Vol. 329, 1987, S. E. Adams et al.: "The expression of hybrid HIV:Ty virus-like particles in yeast", pages 68-70. *

Also Published As

Publication number Publication date
WO1991009872A2 (fr) 1991-07-11
AU653926B2 (en) 1994-10-20
IL96647A0 (en) 1991-09-16
US6248574B1 (en) 2001-06-19
KR920703102A (ko) 1992-12-17
AU7033391A (en) 1991-07-24
JPH05503926A (ja) 1993-06-24
EP0509006A1 (fr) 1992-10-21
CA2071858A1 (fr) 1991-06-14

Similar Documents

Publication Publication Date Title
ATE308558T1 (de) Hiv-1- und hiv-2-peptide zur hemmung von mit membranfusionen in zusammenhang stehenden phänomenen, einschliesslich der übertragung von hiv
ATE286132T1 (de) Dns-fragmente des gag-gens von lav
NZ267803A (en) Synthetic peptides which inhibit hiv transmission and other viral diseases
ATE154610T1 (de) Synthetische vom hiv-gp120-env-protein abgeleitete peptide und ihre anwendung
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
CA2363947A1 (fr) Peptides, antigenes du vih, compositions de vaccins afferentes, trousse de dosage immunologique et methode de detection d'anticorps induits par le vih
WO1991009872A3 (fr) Polypeptides selectivement reactifs avec des anticorps contre le virus d'immunodeficience humaine et vaccins comprenant les polypeptides
GB2336844A (en) Anti-hiv peptides and proteins
CA2057612A1 (fr) Peptides selectionnes de l'antigene specifique au groupe (gag) du virus de l'immunodeficience humaine (vih), sa preparation et son utilisation
AU6393990A (en) Hiv related peptides
EP0293792A3 (fr) Protéines encodées par GAG du virus d'immunodéficience humaine
HK1028065A1 (en) Peptides for the detection of hiv-1-group o.
ATE417108T1 (de) Hiv-2 und siv-1 nukleotidsequenzen
Ivanoff et al. Human immunodeficiency virus antigen.
TH13136EX (th) แอนติเจนของ hiv
PT86752A (pt) Procede pour la preparation de peptides susceptibles d:etre reconnus par des anticorps induits contre des retrovirus d:immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et le cas echeant a la vaccination contre le sida

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP KR

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

CFP Corrected version of a pamphlet front page

Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION

WWE Wipo information: entry into national phase

Ref document number: 2071858

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991901556

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991901556

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991901556

Country of ref document: EP